Zinc vs placebo: Progression to visual loss (loss of 3 or more lines on logMAR chart)
Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Zinc vs placebo Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty). Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane Headline outcomes only | OR 0.87 [0.75, 1] | 2 studies · 3791 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.